Targeting low levels of MIF expression as a potential therapeutic strategy for ALS.
Alfahel L, Gschwendtberger T, Kozareva V, Dumas L, Gibbs R, Kertser A, Baruch K, Zaccai S, Kahn J, Thau-Habermann N, Eggenschwiler R, Sterneckert J, Hermann A, Sundararaman N, Vaibhav V, Van Eyk JE, Rafuse VF, Fraenkel E, Cantz T, Petri S, Israelson A.
Alfahel L, et al. Among authors: kahn j.
Cell Rep Med. 2024 Apr 29:101546. doi: 10.1016/j.xcrm.2024.101546. Online ahead of print.
Cell Rep Med. 2024.
PMID: 38703766